Daiichi Sankyo Company LTD
$4.6M 51 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ipsen Pharma SAS
Ipsen Pharma SAS reported $4,601,804.38 across General Payments, Research, and Ownership to 54 physicians and teaching hospitals across 2,656 transactions.
- $4.6M Top quartile payer
- All-tracks total
- 2,656 Top quartile volume
- Transactions
- 54 Below-median reach
- Recipients
- −$257.0K
- General Payments vs PY2023
Ipsen Pharma SAS reported $4,601,804.38 across all CMS Open Payments tracks (General + Research + Ownership) to 54 physicians and teaching hospitals in Program Year 2024 - ranking #287 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $456,371.60, averaging $85.2K per recipient.
How Ipsen Pharma SAS's $4.6M all-tracks total breaks down
Ipsen Pharma SAS's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
36/100
Total payments
D
53/100
Transaction volume
F
29/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ipsen-pharma-sas Ipsen Pharma SAS
$4.6M · #287/1,925 · 0.0% industry · PY2024
- TOT $4.6M
- RANK #287
- SHARE 0.0%
- TXN 2,656
- RCP 54
- CAT 4
- GEN $456.4K
- ΔGEN −$257.0K
- TOP1 68.4%
- PY 2024
Volume peers
Nearest volume peer: Daiichi Sankyo Company LTD ($4.6M)
Ipsen Pharma SAS sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ipsen Pharma SAS's CMS-reported General Payments decreased by $257.0K (−36.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: IPSEN PHARMA SASPY2023: IPSEN PHARMA SASPY2024: Ipsen Pharma SAS. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $713,418.90
- PY2024
- $456,371.60
What the Data Shows for Ipsen Pharma SAS
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Ipsen Pharma SAS, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 4 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $412.3K across 4 transactions, 90.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Ipsen Pharma SAS's 4-category general-payment breakdown at $412.3K, 90.3% of the reported total.
Ipsen Pharma SAS reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (90.3%), Travel and Lodging (8.5%), and Consulting Fee (0.6%). The remaining 1 category make up 0.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ipsen Pharma SAS divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $412.3K | 4 | 90.3% |
| Travel and Lodging | $38.9K | 19 | 8.5% |
| Consulting Fee | $2.9K | 3 | 0.6% |
| Food and Beverage | $2.3K | 28 | 0.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $442,616.94 (97.0%) of $456,371.60 in this company's General Payments records across 26 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ipsen Pharma SAS
The five named recipients with the highest reported General Payments from this company
- 1
Langley Porter Psychiatric Hospital
$312,303.95 across 1 reported transactions
- 2
The Childrens Hospital Of Philadelp
$99,996.00 across 3 reported transactions
- 3
Lee S Chung
$11,908.13 across 5 reported transactions
- 4
Wuwei Feng
$10,502.60 across 9 reported transactions
- 5
Michael Cecchini
$7,906.26 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ipsen Pharma SAS's spend rank (#287 of 1,925, top 15% by spend) and concentration rank (#334 of 1,838, top 18% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Northgate Technologies, Inc. : $21.4K total payments, HHI 5218
- Janssen Products, LP : $473.97 total payments, HHI 5203
- SPIWay, LLC : $7.0K total payments, HHI 5200
- Forthright Medical - MT, LLC : $100.4K total payments, HHI 5198
- Solco Biomedical Corporation : $18.0K total payments, HHI 5197
- Zentech Inc. : $15.2K total payments, HHI 5181
- Ipsen Pharma SAS (this company) : $456.4K total payments, HHI 5180
- Omega Medical Imaging, LLC : $515.98 total payments, HHI 5180
- Dental Material Gesellschaft mbH : $7.3K total payments, HHI 5160
- Aspero Medical, Inc. : $1.4K total payments, HHI 5153
- Karl Storz Imaging, Inc. : $852.50 total payments, HHI 5150
- Iridex Corporation : $151.0K total payments, HHI 5149
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ipsen Pharma SAS's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ipsen Pharma SAS.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ipsen Pharma SAS.
Showing 6 of 1,924 companies with CMS-reported payment data.
Biotronik Inc.
$4.5M 10,399 recipients
Compare payment profiles
bluebird bio, Inc.
$4.5M 229 recipients
Compare payment profiles
Stemline Therapeutics Inc.
$4.7M 6,314 recipients
Compare payment profiles
Novocure Inc.
$4.5M 3,615 recipients
Compare payment profiles
Novocure GmbH
$4.8M 7 recipients
Compare payment profiles
Put this to use
Ipsen Pharma SAS ranks #287 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Ipsen Pharma SAS sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Ipsen Pharma SAS. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.